INTRODUCTION
Cancer is one of the most deadly diseases responsible for significant mortality and morbidity [1] . Skin cancer being one of the prevalent cancers causes of mortality across the world [1] . In the USA, it is estimated that one in every five Americans is a victim of skin cancer [2] . With the increasing frequency of skin cancer, new treatment approaches need to be developed. Although skin cancer is treated by chemotherapy or surgical interventions, the tumors show frequent relapse [3] . Besides, the adverse effects of synthetic drugs significantly affect the health of the patients.
Flavonoids constitute one the common types of metabolites in the plant kingdom. They form a vital part of almost all edible plant parts which include, but are not limited to fruits and vegetables. It has been shown that humans consume flavonoids in milligrams every day [4] . Flavonoids present in a number of medicinally important plants and herb base medicine have been well-utilized in conventional systems of medicine [5] . With recent developments in the field of medicinal plant research, flavonoids are being screened for a wide array of bioactivities. Some of their pharmacological properties include anti-inflammatory, antibacteral, antifungal, anticancer, and antitumor activities; and inhibition of enzymes [4, 6] .
Several epidemiological investigations on high intake of dietary flavonoids have shown that they are associated with a reduced risk of cancer development [7] . Since flavonoids are prevalent in eatable plants and beverages, they are expected to exhibit negligible toxicity [8] .
In this investigation, the anticancer effects of myricetin were evaluated on A431 skin cancer cell line.
EXPERIMENTAL

Chemicals and reagents
All chemicals and reagents were purchased from Sigma-Aldrich Co. The antibodies were procured from Santa Cruz Biotechnology Inc. The fluorescent probes 4′-6-diamidino-2-phenylindole (DAPI), propidiumiodide (PI), fetal bovine serum (FBS), RPMI-1640 medium, L-glutamine and antibiotics were obtained from Invitrogen Life Technologies.
Cell line and culture conditions
The cell lines skin carcinoma (A431) and normal fibroblasts (FR-2) were procured from Cancer Research Institute of Beijing, China, and were cultured continuously in RPMI-1640 supplemented with 10 % FBS containing antibiotics streptomycin (100 μg/ml))and penicillin G (100 U/ml), and incubated at 37 ˚C in an atmosphere containing 5 % CO 2 .
Anti-proliferative assay
The impact of myricetin on the proliferation rate of A431 cancer cells was investigated using MTT assay. The cells were cultured to 1x10 6 cells per well in 96 well plates for 12 h and then administrated with 0 -100 μM myricetin for 24 h. Thereafter, addition of MTT solution (20 µl) was done. Before the addition of 500µl of DMSO for solubilizing the formazan crystals, dimethylsulfoxide (DMSO, 500 μL) was added. Absorbance was thereafter read in an ELISA plate reader.
Clonogenic assay
To assess the impact of myricetin on the colony development capacity of A431cell lines, the cells were collected at exponential phase of growth and counted using a hemocytometer. The platting of the cells was carried out at 200 cells in each well. The plates were then kept for 48 h at 37 ○ C to allow adhesion. This was followed by the addition of various concentrations (0, 10, 120 and 40 µM) of myricetin. The plates were again subjected to incubation for 6 days, after which they were subjected to washing with FBS and fixed with methanol. The A431 cells were then stained with crystal violet, followed by microscopy, and counted under light microscope.
Apoptosis assay
A431 cells were grown in 6-well platesat1 × 10 6 cells per well and then treated with 0, 10, 20 and 40 µM myricetin for a period of 24 h. This was immediately followed by DAPI staining. The cells were examined and the photomicrographs taken with the help of a fluorescence microscope. Thereafter, the cells were harvested, washed with FBS, and then treated with Annexin V/FITC and Propidium iodide for 20 min. The percentage of apoptotic cells was checked by flow cytometry.
Cell cycle analysis
Approximately 1 x 10
5 cells in each well in 6-well plates were kept at 37 °C for 24 h to allow the cells to adhere and subsequently treated with various doses of myricetin. The cells were then subjected to incubation at 37 ○ C. The distribution of the A431 cells in various cell cycle phases was determined by flow cytometry.
Determination of ROS and MMP
A431cells were grown in six-well plates with a density of 2 × 10 5 cells per well followed by incubation at 37 ○ C overnight. The cells were then subjected to treatment with 0, 10, 20 and 40 µM myricetin for 24 h at 37 °C. The cells were then harvested and subjected to FBS washing. They were then re-suspended in 500 μl of DCFH-DA (10 μM) for determination of ROS, and DiOC 6 (1 μmol/L) for assessment of MMP levels at 37 °C in the dark, for 30 min. The samples were then analyzed using a flow cytometer.
Cell migration and invasion assay
The A431 cells were suspended in 2 % fetal bovine serum (FBS) and placed in an upper chamber with transwells of 8 μm pore size. The medium was subsequently supplemented with 10 % FBS, and the cells were subjected to 24 h incubation at 37 ○ C. The un-migrated A431 cells were removed from the upper side of the membrane, while migrated cells on the lower surface were subjected to fixation with 100 % methanol followed by Giemsa staining. Cell migration was determined by estimating the number of the migrated cells, using microscopy. The cell invasion assay was performed alongside the migration assay as described above, except that the pores were coated with martigel.
Western blotting analysis
A431 cells were lysed and the concentration of the proteins in each cell lysate was determined by BCA assay. The expressions of the proteins of interest were determined by western blotting as described previously [6] .
Statistical analysis
Data are presented as mean ± SD and were statistically analyzed using Students Newman Keul's test or t-test. The levels of significance were determined at p < 0.01, p < 0.001 or p < 0.0001.
RESULTS
Anti-proliferative effects of myricetin on A431 cell line
Myricetin displayed significant anti-cancer effects against A431 cell lines with an IC 50 of 20µM. Nonetheless, its showed lower growth inhibitory activity on normal human FR2 cells (IC 50 of 85 µM). The effect of myricetin on the growth of A431 cells followed a concentration-dependent pattern ( Figure 1A) . It was also observed that myricetin treatment caused significant reduction in A431 colonies dose ( Figure 1B ).
Apoptosis in A431 cells
Myricetin caused apoptotic cell death in A431 cells dose-dependently (Figure 2 ). The analysis of apoptotic cell population was performed with the help of flow cytometry (Figure3). The apoptotic A431 cells augmented from 1.25 % in control to 46.3 % at 40 µM of myricetin. To assess if the apoptosis was due to the activation of mitochondrial apoptotic pathway, the protein expressions of Bax and Bcl-2 were studied. The results showed that while the expression of Bax was increased in a dose-dependent pattern, Bcl-2 expression decreased (Figure 4) .
Activation of ROS and reduction of MMP
It was revealed that the ROS levels of myricetinadministrated cells were increased up to 210 % at 100 µM myricetin ( Figure 5A ). These observations showed that myricetin may trigger apoptosis through accretion of ROS in A431 cells. Reactive oxygen species generation is related to mitochondrial dysfunction. They disrupt the outer mitochondrial potential leading to the discharge of the apoptosis-triggering proteins [9] . Myricetin-treated A431 cells exhibited a dosedependent and significant reduction in MMP. The MMP declined up to 85 % at 100 µM of myricetin ( Figure 5B ). 
Myricetin triggered cell cycle arrest
It was found that the number of the A431 cells at sub-G1 phase increased in a dose-dependent manner causing cell cycle arrest (Figure 6 ). At 40 μ M myricetin, there was a marked increase in sub-G1 phase cells. 
DISCUSSION
Skin cancer is a lethal disease and responsible for considerable deaths in humans, especially among the Caucasians.
The mounting prevalence of skin malignancies demands establishment of multiple and novel treatment approaches [1] . So far, a number of secondary metabolites from plants are used as anticancer drugs [9] . Myricetin is a flavonoid frequently reported to have a wide range of medicinal importance [10] . The effects of myricetin on bladder and thyroid tumors have been reported [10] .
In this study, the anticancer activity of myricetin against A431 human skin cancer cell lines and normal human fibroblasts FR2 cells were evaluated. The results showed that myricetin exerted potent anti-proliferative effects on A431 cells and decreased their colony-forming capacity as was evident from MTT and clonogenic assays, respectively. Many chemotherapeutic agents like cisplatin, taxol and 5-fluorouracil have been observed to induce explicit apoptotic signaling pathways [10, 11] . However, the chemo-resistance of cancer cells to drugs is in part because of the capability of the cells to escape apoptosis [12, 13] .
Results from this study showed that myricetin induces apoptosis in a dose-dependently. Myricetin-treated cells showed ROS-prompted MMP loss. These results are in agreement with previous reports [14, 15] , and suggest that myricetin may induce apoptotic damage via increased production of ROS and decline in MMP.
Several anti-cancer drugs exert growth inhibitory effects on cancer cells by generation of ROS [16] . For instance, capsaicin disrupts MMP and causes oxidative stress causing apoptotic cell death in cancerous pancreatic cells [17] .
The results of the present study are interesting and show great promise in the treatment of skin cancer.
For instance, myricetin significantly inhibited the migration and invasion of skin cancer cells, an indication that it may prove beneficial in halting the metastasis of cancer cells in vivo.
CONCLUSION
The results of this study show that myricetin, by inducing apoptosis and cell cycle arrest, may be a potent lead molecule for the treatment of skin cancer. As a flavonoid, myricetin may exhibit low toxicity, and so deserves further investigations in vivo.
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